Tag Archives: NASDAQ:PDLI

A Director at PDL BioPharma (NASDAQ: PDLI) is Selling Shares

On November 19, a Director at PDL BioPharma (PDLI – Research Report), David Gryska, sold shares of PDLI for $359.5K. See today’s analyst top recommended stocks >> The company has a one-year high of $3.86 and a one-year low of

PDL BioPharma (PDLI) Gets a Hold Rating from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on PDL BioPharma (PDLI – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $3.57. According to TipRanks.com, Nadeau

Analysts Offer Insights on Healthcare Companies: PDL BioPharma (NASDAQ: PDLI) and Albireo Pharma Inc (NASDAQ: ALBO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PDL BioPharma (PDLI – Research Report) and Albireo Pharma Inc (ALBO – Research Report). PDL BioPharma (PDLI) In a report released yesterday, Phil Nadeau from

Cowen & Co. Sticks to Their Hold Rating for PDL BioPharma (PDLI)

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on PDL BioPharma (PDLI – Research Report) today and set a price target of $3. The company’s shares opened today at $2.46. According to TipRanks.com, Nadeau is a 5-star analyst

PDL BioPharma Gets a Hold Rating from Cowen & Co.

In a report issued on June 12, Phil Nadeau from Cowen & Co. maintained a Hold rating on PDL BioPharma (NASDAQ: PDLI), with a price target of $2.50. The company’s shares closed yesterday at $2.70. According to TipRanks.com, Nadeau is

Cowen & Co. Reiterates a Hold Rating on PDL BioPharma

Cowen & Co. analyst Phil Nadeau reiterated a Hold rating on PDL BioPharma (NASDAQ: PDLI) yesterday and set a price target of $3. The company’s shares closed yesterday at $2.96. According to TipRanks.com, Nadeau is a 5-star analyst with an